title: Effect of fluocarbon exchange transfusion on myocardial infarction size in dogs.
abstract: Fluosol DA (20%), a perfluocarbon with high oxygen solubility, was administered by concurrent exchange transfusion (30 ml/kg) to anesthetized open-chested adult greyhounds (n = 9) 1 hour after left anterior descending coronary ligation. Mechanical ventilation using 100% oxygen was used throughout the experiment. A second similar group (n = 9) received 0.9% normal saline solution (30 ml/kg), and a third group (n = 9) received no further intervention. Systemic, right atrial, and left atrial pressures were not altered by the exchange transfusion. Monastryl blue dye was injected through the left atrial line at 6 hours after ligation to define the area of myocardium at risk (AR); the animals were then killed and the heart was excised. The left ventricle was sliced at 5 mm intervals and stained using triphenyltetrazolium chloride, defining areas of necrosis (AN). The ratio of AN/AR and total left ventricular mass were then compared with the use of planimetry. The results were as follows: the AN/AR ratio in the 9 control animals was 90 +/- 2 (mean +/- standard error of the mean); in the 9 animals who received saline solution it was 88 +/- 2; and in the animals who received Fluosol it was 67 +/- 4 (p less than 0.01 compared with control; p less than 0.001 compared with the saline group). Fluocarbon exchange transfusion may reduce infarct size when administered after coronary occlusion.
mesh_terms: D000818:Animals; D001802:Blood Substitutes / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications; D004285:Dogs; D004338:Drug Combinations / Q000627:therapeutic use; D005078:Exchange Transfusion, Whole Blood; D005466:Fluorocarbons / Q000627:therapeutic use*; D006895:Hydroxyethyl Starch Derivatives; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D010100:Oxygen / Q000378:metabolism
chemical_list: D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen